Yes BD - February 11 Dr NP had an interview in AM and then presentation little later.
In the presentation he said that they have some patients now on longer overlap with HAART , and after 10 weeks with some patients efficacy is better.

In phase 3 overlap is one week , first week of study patient is on both HAART and Leronlimab , after one week they stopping HAART and continue Leronlimab.

What they noticed that if they keep patient on HAART little longer , for 5 times half life or Leronlimab results they see are better ,

February 11 it was 10 weeks on treatment with results :

350 mg, 79 patients , 75% efficacy.
525 mg , 101 patients , 90% efficacy.
700 mg , 22 patients, efficacy 100%

Because half life is little different for different dose we are talking how much longer patients need to be on HAART after starting .

I am trying to check , but I feel 18-21 days instead of 7 originally in phase 3 . And Trding research kind of agree with that.

And we feel that in mono update they will talk about it , now is 15 weeks , and most probably pivotal mono will be done with longer overlap if results are still better .